TruTechnologies, a leading provider of real-time clinical trial oversight, today announced Jordan Zwick joined its Board of Directors, bringing extensive experience in corporate strategy and business development to the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250924344534/en/

TruTechnologies announced Jordan Zwick joined its Board of Directors.

Jordan Zwick is Chief Business Officer and a founding team member at Mirador Therapeutics. He previously served as a strategic advisor to Prometheus Biosciences prior to its acquisition by Merck in 2023. He is on the Board of Directors of Theratechnologies Inc., where he played a central role in its recently announced acquisition by Future Pak.

Earlier in his career, Mr. Zwick played a key role in the $14.5 billion sale of Salix Pharmaceuticals to what is now Bausch Health Companies in 2015. Post-sale, he went on to serve as Head of Strategy for the Salix business unit, overseeing business development, strategic partnerships and portfolio management. Throughout his career, Jordan has led capital raises, alliances and transactions, advancing innovation and reshaping companies across the biopharmaceutical industry.

“Jordan’s ability to connect strategy, operations and technology to deliver value across healthcare is exceptional,” said Scott Ogle, CEO of TruTechnologies. “His guidance and industry knowledge will be instrumental as we continue to scale and support sponsors in driving protocol adherence and patient-centric clinical trials.”

“TruTechnologies is uniquely positioned to partner with biotechnology and pharmaceutical companies, together with clinical research organizations and research sites, to accelerate development timelines while increasing probability of technical and regulatory success,” said Jordan Zwick. “I look forward to working closely with Scott and the leadership team to help guide the company through this important stage of growth.”

About TruTechnologies

Founded in 2018, TruTechnologies is the leading provider of real-time clinical trial oversight, focused on enabling timely, high-quality data and mitigating risks in drug development. The company partners with six top 20 pharmaceutical companies and numerous biotechnology firms to accelerate patient screening and enrollment, drive protocol adherence, and correct deviations. Learn more at TruTechnologies.io and follow on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250924344534/en/

"Jordan’s ability to connect strategy, operations and technology to deliver value across healthcare is exceptional. His guidance and industry knowledge will be instrumental."